Jupitab 40 Tablet contains Rosuvastatin 40 mg, a potent lipid-lowering agent belonging to the statin class of medications. It is primarily indicated for the treatment of hypercholesterolemia and mixed dyslipidemia to reduce elevated low-density lipoprotein cholesterol (LDL-C), total cholesterol, and triglycerides, while increasing high-density lipoprotein cholesterol (HDL-C). Rosuvastatin acts by selectively inhibiting HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis, leading to decreased cholesterol production in the liver and increased clearance of LDL particles from the bloodstream. Jupitab 40 is prescribed as an adjunct to diet and lifestyle modifications, including exercise and weight control, to reduce the risk of cardiovascular events such as myocardial infarction, stroke, and angina in patients with established coronary artery disease or multiple risk factors. The tablet is intended for oral administration, typically once daily, with or without food. Dosage adjustments may be necessary based on therapeutic response and patient tolerance. Common side effects include headache, myalgia, and gastrointestinal disturbances. Patients should be monitored for liver function and muscle-related symptoms during therapy. Jupitab 40 should be used cautiously in patients with hepatic or renal impairment and is contraindicated during pregnancy and lactation.